Preliminary study of nanonized lamotrigine containing products for nasal powder formulation
Péter Gieszinger, Ildikó Csóka, Edina Pallagi, Gábor Katona, Orsolya Jójárt-Laczkovich, Piroska Szabó-Révész, Rita Ambrus Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Aff...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2017-08-01
|
| Series: | Drug Design, Development and Therapy |
| Subjects: | |
| Online Access: | https://www.dovepress.com/preliminary-study-of-nanonized-lamotrigine-containing-products-for-nas-peer-reviewed-article-DDDT |
| _version_ | 1831725860785225728 |
|---|---|
| author | Gieszinger P Csóka I Pallagi E Katona G Jójárt-Laczkovich O Szabó-Révész P Ambrus R |
| author_facet | Gieszinger P Csóka I Pallagi E Katona G Jójárt-Laczkovich O Szabó-Révész P Ambrus R |
| author_sort | Gieszinger P |
| collection | DOAJ |
| description | Péter Gieszinger, Ildikó Csóka, Edina Pallagi, Gábor Katona, Orsolya Jójárt-Laczkovich, Piroska Szabó-Révész, Rita Ambrus Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary Abstract: The nasal delivery of drugs offers a great alternative route to avoid adverse events and to increase patient compliance due to its advantageous properties. Besides nasal application, topical, systemic and central effects are also available. Nasal powders (NPs) have better adhesion due to the additive polymers that may be, eg, gelling or good wettability agents; thus, their bioavailability is better compared to the liquid formulations. Using nanoparticles, innovative and more efficient products can be achieved, which may lead to the improvement of different therapies. The aim of this study was to produce NP formulations containing lamotrigine (LAM) as interactive physical mixtures and nanosized LAM-based formulations. After risk assessment of the preliminary tests, the micrometric properties (particle size and morphology) and the structural properties (differential scanning calorimetry [DSC], X-ray powder diffraction [XRPD]) were investigated; thereafter, physicochemical properties (solubility, polarity) and in vitro dissolution and diffusion profiles were also examined. These product samples showed an appropriate particle size ranging 10–25 µm, while the particle size of LAM in the products was between 120 and 230 nm and the dissolved amount of drug was >60% after 5 minutes in these cases. Keywords: nanonization, nasal powder, lamotrigine, co-milling, risk assessment |
| first_indexed | 2024-12-21T04:48:17Z |
| format | Article |
| id | doaj.art-3e6e34c7fe7240698b0ab1b3c99416ce |
| institution | Directory Open Access Journal |
| issn | 1177-8881 |
| language | English |
| last_indexed | 2024-12-21T04:48:17Z |
| publishDate | 2017-08-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Drug Design, Development and Therapy |
| spelling | doaj.art-3e6e34c7fe7240698b0ab1b3c99416ce2022-12-21T19:15:30ZengDove Medical PressDrug Design, Development and Therapy1177-88812017-08-01Volume 112453246634384Preliminary study of nanonized lamotrigine containing products for nasal powder formulationGieszinger PCsóka IPallagi EKatona GJójárt-Laczkovich OSzabó-Révész PAmbrus RPéter Gieszinger, Ildikó Csóka, Edina Pallagi, Gábor Katona, Orsolya Jójárt-Laczkovich, Piroska Szabó-Révész, Rita Ambrus Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, University of Szeged, Szeged, Hungary Abstract: The nasal delivery of drugs offers a great alternative route to avoid adverse events and to increase patient compliance due to its advantageous properties. Besides nasal application, topical, systemic and central effects are also available. Nasal powders (NPs) have better adhesion due to the additive polymers that may be, eg, gelling or good wettability agents; thus, their bioavailability is better compared to the liquid formulations. Using nanoparticles, innovative and more efficient products can be achieved, which may lead to the improvement of different therapies. The aim of this study was to produce NP formulations containing lamotrigine (LAM) as interactive physical mixtures and nanosized LAM-based formulations. After risk assessment of the preliminary tests, the micrometric properties (particle size and morphology) and the structural properties (differential scanning calorimetry [DSC], X-ray powder diffraction [XRPD]) were investigated; thereafter, physicochemical properties (solubility, polarity) and in vitro dissolution and diffusion profiles were also examined. These product samples showed an appropriate particle size ranging 10–25 µm, while the particle size of LAM in the products was between 120 and 230 nm and the dissolved amount of drug was >60% after 5 minutes in these cases. Keywords: nanonization, nasal powder, lamotrigine, co-milling, risk assessmenthttps://www.dovepress.com/preliminary-study-of-nanonized-lamotrigine-containing-products-for-nas-peer-reviewed-article-DDDTnanonizationnasal powderlamotrigineco-millingrisk assessment |
| spellingShingle | Gieszinger P Csóka I Pallagi E Katona G Jójárt-Laczkovich O Szabó-Révész P Ambrus R Preliminary study of nanonized lamotrigine containing products for nasal powder formulation Drug Design, Development and Therapy nanonization nasal powder lamotrigine co-milling risk assessment |
| title | Preliminary study of nanonized lamotrigine containing products for nasal powder formulation |
| title_full | Preliminary study of nanonized lamotrigine containing products for nasal powder formulation |
| title_fullStr | Preliminary study of nanonized lamotrigine containing products for nasal powder formulation |
| title_full_unstemmed | Preliminary study of nanonized lamotrigine containing products for nasal powder formulation |
| title_short | Preliminary study of nanonized lamotrigine containing products for nasal powder formulation |
| title_sort | preliminary study of nanonized lamotrigine containing products for nasal powder formulation |
| topic | nanonization nasal powder lamotrigine co-milling risk assessment |
| url | https://www.dovepress.com/preliminary-study-of-nanonized-lamotrigine-containing-products-for-nas-peer-reviewed-article-DDDT |
| work_keys_str_mv | AT gieszingerp preliminarystudyofnanonizedlamotriginecontainingproductsfornasalpowderformulation AT csokai preliminarystudyofnanonizedlamotriginecontainingproductsfornasalpowderformulation AT pallagie preliminarystudyofnanonizedlamotriginecontainingproductsfornasalpowderformulation AT katonag preliminarystudyofnanonizedlamotriginecontainingproductsfornasalpowderformulation AT jojartlaczkovicho preliminarystudyofnanonizedlamotriginecontainingproductsfornasalpowderformulation AT szaboreveszp preliminarystudyofnanonizedlamotriginecontainingproductsfornasalpowderformulation AT ambrusr preliminarystudyofnanonizedlamotriginecontainingproductsfornasalpowderformulation |